NF-κB1/IKKε Gene Expression and Clinical Activity in Patients With Rheumatoid Arthritis by Sarmiento Salinas, Fabiola Lili et al.
© American Society for Clinical Pathology 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 11
NF-κB1/IKKε Gene Expression and Clinical Activity 
in Patients With Rheumatoid Arthritis
Fabiola Lilí Sarmiento Salinas,1 MSc, Jonnathan Guadalupe Santillán Benítez, PhD,1,2*  
María Dolores Hernández Navarro, PhD,1 Hugo Mendieta Zerón, PhD3  
Laboratory Medicine 49:1:11-17 
DOI: 10.1093/labmed/lmx033
ABSTRACT
Objective: Rheumatoid arthritis (RA) is a systemic and autoimmune 
disorder whose primary characteristic is the chronic inflammation  
of joints. The objective of this study was to evaluate whether there 
was an association between nuclear factor kappa beta1/IKK  
epsilon (NF-κB1/IKKε) gene expression and clinical activity  
in RA.
Methods: Sixty patients with RA were included in the study: 30  
with clinical activity and 30 with clinical remission. NF-κB1/IKKε 
gene expression was performed by real-time quantitative  
polymerase chain reaction through relative quantification with 
Taqman probes. A ROC curve for NF-κB1 and IKKε was also 
constructed.
Results: There were significant differences in NF-κB1 and IKKε gene 
expression (P ≤ .001 and P ≤ .029, respectively) between RA patients 
with clinical activity and clinical remission. The multivariate lineal general 
model showed that the use of nonsteroidal anti-inflammatory drugs 
influenced the NF-κB1 (P = .046) and IKKε (P = .005) expression. The 
ROC curves for the event “clinical activity” showed the greater area under 
the curve for NF-κB1 (0.827, 95% CI 0.717-0.937), P ≤ .001.
Conclusion: Although the use of NSAIDs influences the NF-κB1/IKKε 
pathway, the IKKε expression might be a useful laboratorial analysis to 
evaluate the RA clinical activity.
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Rheumatoid arthritis (RA) is a systemic and autoimmune 
disorder that primarily affects synovial joints. With a female-
to-male ratio of 3:1, its worldwide prevalence is 1%; in 
Latin America, this is 0.5%, and in Mexico, 0.4%.1,2 The 
main symptoms of RA are inflammation and painful joints, 
morning stiffness of 30-minute duration, fatigue, functional 
disability, and, in some cases, fever.3
There exist various risk factors linked with RA as follows: fam-
ily history of RA or autoimmunity, obesity, tobacco consump-
tion, social class, exposure to infectious agents, and genetic 
Abbreviations:
RA, rheumatoid arthritis; IL, interleukin; TNF-α, tumor necrosis factor 
alpha; CICMED, Research Committee of the Medical Sciences Research 
Center; UAEMEX, Autonomous University of the State of Mexico; ACR, 
American College of Rheumatology; CRP, c-reactive protein; TLR, toll-like 
receptor
1Laboratory of Toxicology, Faculty of Chemistry, Autonomous University of 
the State of Mexico, Toluca, Mexico, 2ISSEMyM Medical Center, Metepec, 
Mexico, 3Faculty of Medicine, Autonomous University of the State of 
Mexico, Toluca, Mexico, and Asociación Científica Latina A.C., Mexico.
*To whom correspondence should be addressed. 
jonnathangsb@yahoo.com.mx.
factors, especially the presence of HLA-DR4 polymorphisms, 
such as DRB1*04:01, DRB1*04:05, and DRB1*04:04.4,5
Some transcription factors are involved in the origin and 
progression of chronic inflammatory disorders. Among 
these factors, some family members of the nuclear ena-
bling factor of kappa free light chains of B-cells (NF-κB1) 
are prominent, in that these genes regulate several biologi-
cal processes, such as cell growth and survival, the devel-
opment of tissues and organs, inflammation, and the innate 
immune response. The latter is related with the expression 
of cytokines, cytokine receptors, and histocompatibility 
genes. In contrast, overexpression of the NF-κB1 family 
members has been associated with multiple ailments, such 
as autoimmune diseases, chronic inflammation, neurode-
generative processes, metabolic disorders, and cancer.6
The NF-κB1 signaling pathway is important in RA disease 
progression, in addition to the inflammatory process and 
synovial cell survival. It was also found that NF-κB1 proteins 
are capable of stimulating the secretion of inflammatory 
cytokines, such as interleukin (IL)-6 and tumor necrosis fac-
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they stimulate the production of IL-2. Likewise, they can 
suppress the production of type II collagen, an essential 
compound of cartilage.7,8 The objective of this study was to 
evaluate whether there was an association between the NF-
κB1/IKKε gene expression and the RA clinical activity.
Material and Methods
Experimental Design
A prospective cross-sectional study was conducted at 
the Rheumatology Service, ISSEMyM Medical Center, 
Metepec, State of Mexico, Mexico, from November 
2013 to June 2014. The study was approved by the 
Research Committee of the Medical Sciences Research 
Center (CICMED), Autonomous University of the State 
of Mexico (UAEMex), and the ISSEMyM Medical Center 
(code 038/13). The process complied with the eth-
ical principles of the Declaration of Helsinki and of the 
Official Mexican Norm (NOM-012-SSA3-2012) for medical 
research in humans,9 and registered at ClinicalTrials.gov 
(NCT02689115); written informed consent was obtained 
from all subjects.
Patients
The key inclusion criteria were patients with RA who 
met the criteria established by the American College of 
Rheumatology (ACR).10 Two groups were conformed based 
on the Disease Activity Score 28 (DAS28),11 1) with clin-
ical activity (DAS28 > 3.6) and 2) with clinical remission 
(DAS28 < 2.4). Key exclusion criteria included patients 
with any other inflammatory or autoimmune disease, and 
patients with infections.
Sample Size










Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a 
2-sided test, 28 subjects per group were necessary to rec-
ognize a statistically significant difference greater than or 
equal to 3 relative expression units (fold changes). The com-
mon standard deviation was assumed to be 4, based on a 
previous publication12 in which the same genes were used.
Anthropometric Measurements
Weight (kg) and height (m) were calculated in a mechanical 
column scale (Seca brand). Patients were classified accord-
ing to their body mass index (BMI) and weight (kg)/height 
(m2) as follows: 1) normal weight (BMI <24.9 kg/m2), 2) over-
weight (BMI >24/9 kg/m2 and <29.9 kg/m2), and 3) obese 
(BMI >30 kg/m2).
Lymphocyte Extraction
Lymphocytes from peripheral blood were extracted using 
the ACK Lysing Buffer (Life Technologies, Grand Island, NY) 
kit. Briefly, a venous blood sample (2.5 mL) in an EDTA tube 
(BD Vacutainer; BD, Franklin Lakes, NJ) was centrifuged at 
3500 rpm during 5-8 minutes. The resulting buffy coat was 
extracted and placed in an Eppendorf tube; 1 mL of ACK 
Lysing Buffer was added and carefully resuspended. Once 
again, the suspension was centrifuged at 1900 rcf during 
5-8 minutes, and the supernatant was discarded. This 
latter step was repeated until the leukocyte package (4000-
10,000 cells) was completely white (approximately 10-15 
mg). Finally, 100 uL of ACK Lysing Buffer was added, and 
this was frozen at –70ºC for later use.
Gene Expression
From the leukocyte lysate, a messenger RNA (mRNA) 
extraction was performed using the Magna Pure LC 
RNA Isolation Kit III (Roche) in the Magna Pure LC 2.0 
Instrument. The A260-280-nm absorbance ratio was 
>1.8 (quality), and total RNA concentration (ng/uL) was 
calculated by determining absorbance at 260 nm with a 
NanoPhotometer (Implen GmbH, Germany).
Subsequently, the complementary DNA (cDNA) was syn-
thesized with the Transcriptor High Fidelity cDNA Synthesis 
Kit (Roche Applied Science); 100 ng of RNA in a final 
volume of 15 uL was used per reaction. The quantitative 
polymerase chain reaction (qPCR) was performed utilizing 
a 7500 Fast Real-Time PCR System (Applied Biosystems, 
Applera UK, Cheshire, UK), mixing TaqMan Universal PCR 
Master Mix and the specific probes (Applied Biosystems) 
for each gene, including NF-κB1 (Hs00765730-m1), IKKε 
(Hs01063858-m1), and 18S (Hs99999901-s1); the last was 
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used as a control gene. The conditions for the qPCR are 
depicted in Table 1.
According to the CT obtained from the 2 different groups, 
relative expression was calculated by the fold change in 
NF KB, and IKK was normalized against the constitutively 
expressed reference genes, then compared to the untreated 
controls (calibration sample) as follows: 2 − ΔΔCT, where 
ΔΔCT = (CT-target − CT-reference) treated-sample − 
(CT-target − CT-reference) calibrator-sample. Calibrator 
-sample refers to the expression level (1×) of the target gene 
normalized to the constitutive gene. The calibrator was cho-
sen from the group with clinical activity and given a relative 
expression value of 1.13
Statistical Analysis
The correlation among NF-κB1, IKKε and DAS28 was per-
formed through the Spearman test. The multivariate lineal 
general model was used to evaluate the drug effect on the 
NF-κB1 and IKKε RU and DAS28 punctuation. For the 2 
genes, ROC curves with the area under the curve (AUC) and 
95% confidence interval (CI) were constructed for the event 
“clinical activity.” Finally we evaluated the best curve model 
for both genes and the clinical activity. Any P value ≤ .05 
was considered significant. All tests were performed with 
the SPSS v 15 software (SPSS, Chicago, IL).
Results
From a total of 680 patients attended in the aforemen-
tioned period, 60 patients were included in the study, 
mean age 52 ± 11.62 years, 30 with clinical activity (28 
women and 2 men) and 30 in clinical remission (26 women 
and 4 men). From the first group, 6 patients had high activ-
ity (DAS28 >5.1) and 24 moderate activity (DAS28 <3.2). 
Table 2 shows the DAS28 score, anthropometric meas-
urements, biochemical values, and NF-κB1/IKKε gene 
expression, and in Table 3 the CT values of each sample 
and gene are displayed. Whilst the anthropometric meas-
urements did not demonstrate significant differences, the 
converse occurred in the gene expression of both NF-κB1 
(P ≤ .001) and IKKε (P = .008). In contrast, while the NF-
κB1 expression was detected in all cases, IKKε expression 
was confirmed in 16 patients with clinical activity and only 
in three with clinical remission. The intragroup analysis 
between moderate and high clinical activity using the 
Mann-Whitney U test did not show any significant differ-
ence for the 2 target genes.
The Kolmogorov test showed a non-Gaussian distribution 
for the 2 tested genes. Therefore, the Spearman correl-
ation test was performed with the previous 2 genes and the 
DAS28 scale punctuation, resulting in a significant positive 
correlation between NF-κB1 and DAS 28 (r2 = .495, P ≤ 
.001). Notoriously, 25 patients (83.33%) in the group of clin-
ical activity and 26 (26.66%) in the group of clinical remis-
sion were prescribed nonsteroidal anti-inflammatory drugs 
(NSAIDs). In both groups, the most common combination of 
drugs was a disease-modifying antirheumatic drug plus an 
NSAID. The multivariate lineal general model showed that 
the use of NSAIDs influenced the NF-κB1 (P = .046) and 
IKKε (P = .005) relative expression. Moreover, when compar-
ing the expression of both genes, contrasting the use of the 
drug family, there was a significant difference in IKKε when 
the patients were in NSAIDs treatment (P = .003; Table 4).
Finally, through the ROC curves, including the missing 
values, the AUC (95% CI) for NF-κB1 and IKKε were 0.827 
Table 1. Conditions for the Quantiative Polymerase 
Chain Reaction 
 Component Volume (1 tube) 10% Error
TaqMan Gene Assay (uL) 1.0 1.1
TaqMan UNIVERSAL (uL) 10.0 11.0
H
2
O PCR (uL) 9-sample volume 9-sample volume
Total (uL) 20 22.0
Sample volume = uL of sample to use 100 ng cDNA.
Table 2. General Data of the Patients





Age (years) 50.0 ± 10.4 54.0 ± 12.8
BMI (kg/m2) 26.3 ± 4.3 25.7 ± 4.3
CRP (mg/L) 15.7 ± 18.0 4.6 ± 6.2 .001
DAS28 (points) 4.3 ± 0.7 1.4 ± 0.5 .001
Glucose (mg/dL) 94.2 ± 16.9 109.2 ± 43.1
NF-κB1(RE) 3.73 ± 2.67 0.693 ± 0.079 ≤.001
IKKε (RE) 0.48 ± 0.36 0.00103 ± 0.0008 .008
Values expressed in Mean ± SD. 
BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score 28; 
IKKε, activating kinase of NF-kB, NF-κB1, nuclear factor kappa-light-chain-enhancer 
of activated B cells; RE, relative expression.
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(0.717-937), P ≤ .001; and 0.550 (400-700), P = .506, 
respectively (Figure 1).
Taking into account the effect of NSAIDs, we proceeded to 
evaluate the best curve estimation for our dataset, leading 
to the logarithmic and potency models as those that fit bet-
ter with our data (P ≤ .001).
It is worth noting that 11 patients from the group of clinical 
activity suffered from at least 1 episode of infection, while in 
the group of clinical remission, only 6 had this kind of com-
plication. The type of drugs that the patients were taking is 
depicted in Table 5.
Discussion
It is important to specify that, among the group of patients 
without clinical activity, the majority recorded no amplifi-
cation in the IKKε transcript, in contrast with patients with 
active RA, in whom important variations in the relative 
expression were observed.
Different studies have linked NF-kB overexpression with 
inflammatory and autoimmune processes in diseases such as 
Table 3. CP Values of NF-kB1 and IKKε for Each Sample
NF-kB 18s Δ Cp ΔΔ Cp RE IKKε 18s Δ Cp ΔΔ Cp RE
25.0000 5.5393 19.4607 5.7904 0.0181 26.7779 5.5393 21.2386 3.0647 0.1195
30.7914 15.3075 15.4839 1.8136 0.2845 34.8692 15.3075 19.5617 1.3878 0.3821
32.6788 19.2121 13.4667 –0.2036 1.1516 37.0690 19.2121 17.8569 –0.3170 1.2457
33.4393 20.0963 13.3430 –0.3273 1.2547 40.7389 20.0963 20.6426 2.4687 0.1807
32.8940 19.9053 12.9887 –0.6816 1.6039 35.0393 19.9053 15.1340 –3.0399 8.2243
33.7067 20.9540 12.7527 –0.9176 1.8890 39.5728 20.9540 18.6188 0.4449 0.7346
26.9489 14.3496 12.5993 –1.0710 2.1009 29.5089 14.3496 15.1593 –3.0146 8.0814
27.0737 14.5858 12.4879 –1.1824 2.2695 28.3908 14.5858 13.8050 –4.3689 20.6619
28.9228 16.5027 12.4201 –1.2502 2.3787 36.0770 16.5027 19.5743 1.4004 0.3788
29.0183 16.9648 12.0535 –1.6168 3.0669 35.2065 16.9648 18.2417 0.0678 0.9541
33.2223 21.8552 11.3671 –2.3032 4.9355 34.3395 21.8552 12.4843 undet undet
32.3036 21.0941 11.2095 –2.4608 5.5052 undet 21.0941 undet undet undet
32.7965 21.6030 11.1935 –2.4768 5.5666 undet 21.6030 undet undet undet
30.6586 19.4880 11.1706 –2.4997 5.6557 34.5901 19.4880 15.1021 –3.0718 8.4082
35.1412 24.1934 10.9478 –2.7225 6.6002 undet 24.1934 undet undet undet
31.9580 21.0205 10.9375 –2.7328 6.6474 undet 21.0205 undet undet undet
28.4964 17.7251 10.7713 –2.8990 7.4591 undet 17.7251 undet undet undet
28.9882 18.4591 10.5291 –3.1412 8.8226 undet 18.4591 undet undet undet
36.0000 26.0000 10.0000 –3.6703 12.7312 undet 26.0000 undet undet undet
20.1220 12.9099 7.2121 –6.4582 87.9249 37.0000 12.9099 24.0901 5.9162 0.0166
26.9021 20.2115 6.6906 –6.9797 126.2115 undet 20.2115 undet undet undet
31.8488 25.8880 5.9608 –7.7095 209.3104 43.9633 25.8880 18.0753 –0.0986 1.0707
36.2823 31.0425 5.2398 –8.4305 345.0113 undet 31.0425 undet undet undet
37.5928 32.5989 4.9939 –8.6764 409.1256 undet 32.5989 undet undet undet
36.0468 31.2345 4.8123 –8.8580 464.0061 undet 31.2345 undet undet undet
21.8182 17.0752 4.7430 –8.9273 486.8387 undet 17.0752 undet undet undet
35.6058 31.2212 4.3846 –9.2857 624.1288 undet 31.2212 undet undet undet
30.6817 26.3407 4.3410 –9.3293 643.2787 35.1887 26.3407 8.8480 –9.3259 641.7644
35.2823 33.0425 2.2398 –11.4305 2760.0908 undet 33.0425 undet undet undet
33.1743 31.4528 1.7215 –11.9488 3953.1857 undet 31.4528 undet undet undet
Cp: crossing point, IKKε: Activating Kinase of NF-kB, NF-κB1: Nuclear factor kappa-light-chain-enhancer of activated B cells, RE: relative expression, undet: undetermined.
Table  4. Difference in the IKKε Expression by 
Drug Treatment
Levene Test t-Test
F Sig t Sig (bilateral) 95% CI
Biological 3.356 0.087 0.862 0.402 (–97.7-230.5)
NSAIDs 13586.354 0.000 3.607 0.003 (130.1-505.9)
Steroid 1.308 0.271 0.554 0.588 (–142.9-243.3)
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RA, systemic lupus erythematosus (SLE), and psoriasis.14–17 
However, there is no clear information on whether there is a 
link between clinical activity and NF-κB1 gene expression 
adjusting the results to the pharmacological treatment.
In this study, we show that there does exist a significant 
difference between the degree of NF-κB1 expression of 
patients with clinical disease activity vs those with clinical 
remission. Thus, it is possible to suggest that these path-
ways may be therapeutic targets in RA, in that there is higher 
expression in patients with clinical activity compared with 
patients with clinical remission. This especially applies if it 
is considered as background that the NF-κB1 family com-
prises transcription factors that stimulate the synthesis of 
various inflammatory cytokines involved in RA inception and 
development, such as IL-1, IL-6, and TNF-α. Therefore, reg-
ulating the expression of these transcripts could be a future 
therapeutic alternative. This is also suggested as a possible 
inflammatory biomarker, because the clinical activity is dir-
ectly linked with the presence of the inflammatory process.
In the case of IKKε, it is noteworthy that it is a gene triggered 
by a severe inflammatory stimulus, and that it is expressed 
predominantly in the cells and tissues of the immune system; 
it has been described, specifically, that the primary activity of 
IKKε is the chronic activation of synovial inflammation in an 
arthritic joint;18 thus, as expected, a significant difference was 
found between patients without inflammation and patients 
with inflammation. Consequently, it is possible to suggest that 
IKKε may be considered in this physiopathology, in that its 
expression is linked with chronic inflammation and depends 
on the quite severe inflammatory stimulus, 2 visible aspects in 
a patient with clinical activity. While further work is required to 
define in detail the role of IKKε in RA, it could be considered 
an activity indicator, because an important percentage of 
patients in clinical remission had undetectable levels of IKKε 
expression, contrary to patients with disease activity.
Our results demonstrate a clear difference in the expres-
sion of NF-κB1/IKKε in peripheral blood mononuclear cells 
depending on the clinical activity. Whether this finding can 
be extrapolated to the joint where disease occurs is some-
thing to be corroborated, but the molecular mechanism 
leading to erosions and periarticular and generalized osteo-
porosis in RA suggest so.19 Furthermore, the damage to the 
joints can be modified by the antirheumatic drug group.20
During this research, other aspects linked to the RA were 
also evaluated; this is the case of BMI. The literature reports 
that obesity is considered at present a low-grade inflamma-
tory pathology whose consequence is the increase of the 
plasmatic levels of proinflammatory cytokines such as TNF-
α and acute-phase reactants, such as the C-reactive protein 
(CRP).21,22 Obesity is also considered a risk factor for RA. 
This has been reported in studies in which it was observed 
that with regard to the levels of leptin and other types of 
adipokines that regulate different physiological functions, 
including the immune response, these levels are elevated 
in those with obesity. This represents a strong connection 
with obesity under diverse autoimmune conditions, such 
as RA, SLE, type 1 diabetes, and Hashimoto thyroiditis.23,24 
Conversely, other authors suggest that being overweight 
only adds a traumatic load to the joints and that, subse-
quently, there exists a higher predisposition to suffer osteo-
arthritis, a mechanical but not a metabolic problem, and the 
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However, in the present study, there was no difference 
in the degree of NF-κΒ1/IKKε gene expression among 
patients with normal weight, overweight, and obesity, both 
for the group with clinical activity and for that with clinical 
remission. A significant difference was not recorded in the 
BMI, the weight, or the height of both groups. Therefore, 
it is suggested that overweight and obesity constitute 
probable risk factors in the development of the disease 
because currently, obesity is considered a minor inflamma-
tory process. Notwithstanding, this has no connection with 
clinical activity. In this regard, the main causes for a clinical 
improvement are treatment adherence, treatment response, 
application of attenuated-virus vaccines, and recurrent 
infections. The latter triggers the immune response and 
the production of proteins that give rise to inflammatory 
processes, such as TNF-α, 1 of the cytokines of major rele-
vance in the clinical activity of patients with RA.
In addition, we chose to perform a biochemical analysis on 
each patient in which the glucose was considered, because 
some studies mention that patients with RA and active dis-
ease exhibit strong resistance to the elevation-induced insulin 
of TNF-α. Based on this presumption, the patients with mod-
erate-to-high clinical activity would be expected to demon-
strate higher levels of glucose than patients with clinical 
remission; however, the results showed that no differences in 
the glucose levels of both groups, although it is possible that 
this is due to patients undergoing treatment for RA.27–29
Both groups were analyzed depending on the treatment, 
without finding any significant difference in BMI, NF-κB1 
and IKKε. This was unexpected since the biological treat-
ment is focused on suppressing TNF-α,30–32 the primary 
activator in the NF-κB1 signaling pathway by its canonical 
or classic pathway. By contrast, IKKε belongs to an alter-
native pathway that is different from the already known 
pathways and does not depend on TNF-α to be triggered; 
thus, it should not be affected by the biological treatment.33 
However, the multivariate lineal general model showed that 
NSAIDs use influences the NF-κB1 and IKKε expression.
Importantly, this pathway appears to have cell type-specific 
functions, and since many different cell types are involved 
in the pathogenesis of RA, it is difficult to predict the net 
overall contribution of the non-canonical NF-κB pathway 
to synovial inflammation, or clinical indication, and on the 
other hand, as we propose with this study, this will allow 
the design of better therapeutic strategies for the manage-
ment of this disease, including cell type-specific inhibitors 
or selective targeting of inhibitors to certain cell types. 
Some authors propose that NF-κB pathway is a promising 
new therapeutic target, not only in RA, but also in other 
immune-mediated inflammatory diseases.34,35
Finally, there is a latent possibility of biased results due to the 
infections in the group with clinical activity. As it is known, 
NFκB transcription factors are activated upon infection, via 
triggering of various sensors, like the TLRs (toll-like recep-
tors), which are expressed on cells of the innate immune 
system, including macrophages, dendritic cells, and mucosal 
epithelial cells.36 Surprisingly, information is scarce about RA, 
infections, and the activation of the NFκB/IKKε module.37,38
We are aware that a clear limitation of this study is that the 
elected genes might be difficult to quantify in an everyday 
medical practice, but in a second- or third-level hospital 
with a rheumatology service, they could help to identify 
patients without clinical improvement. Thus, the major 
strength of our study is the identification of IKKε as clearly 
positive in RA patients with clinical activity and its negativity 
in 90% of patients in clinical remission. LM
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